Rationale Chronic ethanol (EtOH) treatment decreases the motor-impairing effects of cannabinoids and downregulates the cannabinoid type 1 (CB1) receptor. However, these studies have been limited to measures of ataxia and analysis of CB1 expression from whole-brain or hippocampal preparations. Objective To more fully assess the interactions between ethanol and cannabinoids, a tetrad of four wellcharacterized cannabinoid-induced behaviors (hypolocomotion, antinociception, hypothermia, and catalepsy) was measured in mice following EtOH treatment. Additionally, immunoblotting assessed CB1 protein in tissue from nine brain regions associated with these behaviors and the addiction neurocircuitry.
Introduction
Alcohol dependence and abuse are devastating disorders that affect an estimated one in ten Americans and cost the US economy in excess of US $185 billion annually (NIAAA 2009) . Alcohol use disorders are often comorbid with abuse of other substances including cannabis or marijuana, and both animal and human studies suggest that alcohol and cannabinoids interact in ways that contribute to addiction pathology. For example, it has long been known that cannabinoids and ethanol (EtOH) produce a cross-tolerance to one another (da Silva et al. 2001; Lemos et al. 2007; MacAvoy and Marks 1975; Newman et al. 1974; Newman et al. 1972; Siemens and Doyle 1979; Sprague and Craigmill 1976) . The majority of this work used rodents and examined the ataxic effects of each drug using either a rotorod (da Silva et al. 2001; Siemens and Doyle 1979; Sprague and Craigmill 1976) or tilting plane apparatus (Lemos et al. 2007) . Two studies have also reported cross-tolerance to a learned escape behavior in a one-way avoidance apparatus (Newman et al. 1974; Newman et al. 1972) . Despite these interesting findings, it is not known whether cross-tolerance develops between EtOH and cannabinoids for well-characterized cannabinoid type 1 (CB1)-dependent behaviors.
In rodents, acute administration of a CB1 agonist produces a syndrome of four behaviors known as the tetrad. The tetrad consists of decreased locomotor activity, hypothermia, antinociception, and catalepsy . These effects are produced via activation of the CB1 receptor, a G protein-coupled receptor that is highly expressed throughout the brain (Zimmer et al. 1999) . Because the tetrad is convenient and highly reproducible, it is often employed as a behavioral assay to screen novel compounds for cannabinomimetic activity (Compton et al. 1992 ) and to assess cross-tolerance between cannabinoid substances (Fan et al. 1994 ). To our knowledge, the mouse tetrad has not been used previously to test for crosstolerance between cannabinoids and EtOH.
Therefore, in this study, we used the mouse tetrad to assess whether repeated exposures to EtOH lead to crosstolerance to the effects of an acute CB1 agonist. The results from these studies suggest that chronic EtOH produces a significant cross-tolerance to three of the behaviors in the tetrad. Chronic EtOH treatment produces parallel reductions in both CB1 receptor expression (Basavarajappa et al. 1998; Mitrirattanakul et al. 2007) and function (Basavarajappa and Hungund 1999b) . Accordingly, in the present study, western blots were used to determine if changes in CB1 expression represent a possible mechanism for the altered behavioral response to a CB1 agonist following repeated EtOH treatment.
Methods

Subjects
Male C57BL/6J mice (22-30 g) were purchased from Jackson Laboratories (Bar Harbor, ME) and group housed (four per cage). CNR1 −/− mice on a C57BL/6 background were kindly provided by Dr. David Lovinger, NIAAA, Rockville, MD and were housed under similar conditions.
Mice were maintained on a 12:12 light/dark cycle (lights on at 0600 hours) and given ad libitum access to food and water throughout the experiment. For behavioral experiments, mice were removed from the colony at the end of the light cycle, and experiments continued through beginning of the dark cycle. All experimental protocols were approved by the Institutional Animal Care and Use Committee at MUSC and were in accordance with the Guide for Care and Use of Laboratory Animals (NIH Publication No. 80-23, revised 1996) .
Drugs
EtOH was administered intraperitoneally (i.p.) in a volume of 0.03 mL/g in order to keep the concentration of EtOH below 18%. The CB1 agonist WIN 55212-2 mesylate (WIN; Tocris Bioscience, Ellisville, MO) was first dissolved in Tocrisolve 100 and then diluted with 0.9% saline to give a final concentration of 1.5% Tocrisolve. WIN solutions were injected i.p. in 0.02-mL/g injection volumes.
Ten-day EtOH treatment
Mice were handled daily for 1 week prior to experimental manipulation and then given injections of EtOH (2 or 4 g/ kg; i.p.) or saline twice daily for ten consecutive days. Injections were spaced 8 h apart such that the second injection coincided with the onset of the dark cycle. One or 10 days following the 10-day treatment, mice were used for behavioral testing or tissue collection (Fig. 1a) . Subjects used for western blot analysis underwent retroorbital bleeding during the first ethanol injection on days 1 and 10 of treatment for analysis of blood ethanol concentration (BEC). BEC analysis was performed using a modified version of the colorimetric alcohol oxidase assay described by Prencipe et al. (1987) . The 4.0 g/kg dose of EtOH yielded BECs of 414.1±17.8 mg/dL 20 min following the injection on day 1 of treatment, and 490.2± 12.3 mg/dL at the same time point on day 10. The change in BEC between the 20-and 60-min time points was calculated for day 1 and day 10 of treatment to estimate the rate of change in BEC before and after treatment. There was no significant decrease in this measure following 10-day EtOH treatment (paired t test, p=0.1209) suggesting metabolic tolerance to EtOH does not develop over the 10-day treatment regimen.
Mouse tetrad
Mice were tested for locomotor activity, nociception, body temperature, and immobility (i.e., catalepsy) as previously described (Fig. 1b; Martin et al. 1991) . Each subject was used in the tetrad only once as tolerance can develop to CB1 agonists even after a single administration (unpublished observation). Prior to drug administration, baseline measurements of body temperature and nociception were determined, and mice were habituated to the locomotor activity boxes (Digiscan Animal Activity Monitors, Omnitech Electronics, Inc., Columbus, OH) for 30 min. After injection with WIN (0, 1, 3, or 7 mg/kg), mice were immediately placed back in the activity boxes for 25 min during which locomotor data were collected (VersaMax Software v4, Accuscan Instruments, Inc., Columbus, OH). Horizontal locomotor data during the last 10 min were used for analysis and are presented as the number of optical beam breaks.
Nociception was measured 35 min after WIN injection using a Hot Plate Analgesia Meter (Columbus Instruments, Columbus, OH) set to 56°C. Latency to respond to the heated surface was measured and included jumping or hindpaw licking or fanning. Forepaw responses were not counted because these can be confounded by grooming behaviors (Bannon and Malmberg 2007) . Subjects were removed from the hot plate immediately after making one of the three qualifying responses or at the end of 30 s if they failed to respond. Antinociception data are presented as the percent maximal possible effect (%MPE) where:
Body temperature was measured 45 min post-injection using a rectal probe (Physitemp Instruments, Clifton, NJ), and is expressed as the change in body temperature from the pre-drug baseline.
Catalepsy was assessed 55 min after the WIN injection using the ring test described by Pertwee (1972) . Briefly, mice were placed on the ring with their forepaws gripping one side and their hindpaws on the other. Catalepsy was measured as the time spent immobile in a 5-min period with exception to movements associated with respiration and regaining their starting position. In rare cases, subjects displayed hyper-reflexive behaviors when placed on the ring. In these instances, data were excluded from analysis if an animal fell or jumped five or more times during the 5-min observation period. Data for WIN-induced catalepsy are expressed as the percent of total time spent immobile to the total time on the ring.
CB1 protein
Following a 10-day treatment with 4.0 g/kg EtOH or saline, mice were placed back in their home cages for 1 or 10 days prior to sacrifice. Animals were rapidly euthanized by decapitation, and the brains were immediately immersed for 1-2 min in ice-cold dissection buffer containing (in millimolars): 200 sucrose, 1.9 KCl, 6 MgCl 2 , 0.5 CaCl 2 , 10 glucose, 0.4 ascorbic acid, 25 HEPES, pH 7.3 with KOH. Brains were sectioned into 2-mm-thick coronal slices using an adult mouse brain matrix (ASI Instruments, Warren, MI). From each mouse, nine brain regions were collected for western blot analysis (Supplemental Figure 1) . For the frontal cortices, the olfactory bulbs were first removed, and the medial portion of frontal cortex containing prelimbic, cingulate, medial orbital, and secondary motor cortex was separated from the lateral aspect containing primary motor, Fig. 1 Summary of EtOH treatment and testing regimen. a Mice were administered saline or EtOH (2 or 4 g/kg) i.p. twice per day for ten consecutive days. Following the last injection, subjects were returned to their home cage for 24 h (bottom panel) or 10 days prior to behavioral testing or tissue collection for CB1 protein quantification (top panel). b Timeline of behavioral measures taken as part of the mouse tetrad assay lateral orbital, and frontal association cortices. A 2-mm punch of dorsal striatum (DStr) and a 1-mm punch of the nucleus accumbens (NAc) were made from the next slab. Dorsal hippocampus and the hypothalamus (HyTh) were dissected from the third slab, and 2-mm punches from the fourth slab were used to separate tissue containing periaqueductal gray (PAG) and ventral tegmental area (VTA). Finally, the cerebellum (Cereb) was dissected from the brain stem. Tissue samples were also prepared from CNR1 −/− mice to test the specificity of the anti-CB1 antibody. Following dissection, a crude membrane fraction was prepared, and tissue samples were used for western blotting as previously described (Mulholland and Chandler 2010) . After separation on NuPage Novex gels (4-12% Bis-Tris; Invitrogen Corp., Carlsbad, CA), protein was transferred to Immobilon-P PVDF membranes (Millipore Corporation, Billerica, MA). Membranes were blocked in 1% nonfat dry milk plus 5% BSA and incubated at 4°C overnight in a 1:500 dilution of the L15 anti-CB1 primary antibody (kindly provided by Dr. Ken Mackie, Indiana University, Bloomington, IN). A horseradish peroxidase-conjugated goat antirabbit secondary antibody was then added, and bands were detected using enhanced chemiluminescence (ECL). The band corresponding to the molecular weight of CB1 (≈52 kDa) was quantified using computer-assisted densitometry with ImageJ v1.41 (National Institutes of Health, USA). Following development with ECL, each membrane was stained with Coomasie Brilliant Blue R-250 (Fisher Scientific, Pittsburgh, PA), air-dried overnight, and scanned at 600 dpi to measure total protein (Aldridge et al. 2008) . These values were used to normalize the optical density value of the CB1 band from the corresponding lane. Data are expressed as the fraction of control for each condition.
Statistics
All analyses were performed using Prism GraphPad Software v4.0c (La Jolla, CA). Data from studies assessing tetrad behaviors and CB1 protein expression were analyzed using analysis of variance (ANOVA). Post hoc analyses (Bonferroni posttests) were conducted when appropriate. Significance criteria were established as α=0.05 (twotailed) for all analyses.
Results
Dose dependence of CB1R-induced behaviors
As previously reported (Compton et al. 1992) , acute injection of mice with the CB1 agonist WIN produced hypolocomotion, antinociception, hypothermia, and catalepsy ( Fig. 2 ; one-way ANOVA, p<0.0001). The hypothermic effects of WIN were significantly different from the baseline at all doses tested (Bonferroni's test, p< 0.001), and the antinociceptive effects differed between all doses (p<0.01-0.001) except 0 and 1 mg/kg (p>0.05). For measures of catalepsy and locomotor activity, Bonferroni's multiple comparison test revealed significant differences between all doses tested (p<0.05-0.001) except between the 3-and 7-mg/kg dose (p>0.05), indicating a ceiling effect at the higher doses. Since the 3-mg/kg dose was at or very near the maximal observed effect for all tetrad behaviors (Fig. 2) and because we hypothesized a decrease in sensitivity to CB1 agonists following EtOH treatment, we used 3 mg/kg WIN for all subsequent studies.
Ten-day EtOH treatment decreases sensitivity to WIN
A separate group of naïve male C57 mice were administered EtOH (0, 2, or 4 g/kg, i.p.) twice daily for ten consecutive days. Twenty-four hours following the last EtOH injection, the mouse tetrad was used to assess the effects of WIN (Fig. 3) . Baseline measures of body temperature for the control, 2 g/ kg, and 4 g/kg EtOH groups were 37.63±0.17, 37.48±0.13, and 37.99±0.14 (mean±SEM in degree Celsius), respectively, and these values were not significantly different (one-way ANOVA, p=0.0552). Similarly, baseline measures of hot plate latency did not differ between groups (one-way ANOVA, p=0.3922). These values were 6.392±0.6728, 6.500±0.5177, and 7.431±0.5698 (mean±SEM in seconds) for the control, 2 g/kg, and 4 g/kg EtOH groups, respectively. Overall, the 10-day EtOH treatment significantly reduced the hypolocomotor effects of WIN (one-way ANOVA, p< 0.001). This effect was statistically significant for the 4.0-g/ kg dose and mice treated with the 2.0-g/kg EtOH showed a clear trend towards reduced sensitivity. The antinociceptive effect of WIN was also reduced by EtOH treatment (one-way ANOVA, p<0.0001), and there were significant differences in WIN sensitivity between all treatment groups (Bonferroni posttest, p<0.01-0.001). WIN-induced hypothermia was also blunted in mice that had been previously treated with EtOH (one-way ANOVA, p<0.001), and this effect was similar for both doses of ethanol (Bonferroni posttest, p> 0.05). In contrast to these findings, repeated treatment of mice with either dose of ethanol failed to alter WIN-induced catalepsy (one-way ANOVA, p=0.7607).
EtOH's effect on WIN-induced behaviors is reversible
Two separate groups of mice were administered either saline or 4.0-g/kg EtOH twice daily for 10 days followed by a 10-day no-treatment period. On day 20, baseline measures of body temperature and hot plate latency were assessed prior to measurement of WIN-induced hypolocomotion, antinociception, hypothermia, and catalepsy. To determine if there was an interaction between days of recovery and treatment, tetrad data from day 11 and day 20 for the saline and 4.0-g/kg EtOH treatments were analyzed by two-way ANOVAs (Fig. 4) . Data from the saline and 4.0-g/kg groups in the previous experiment (Fig. 3) were used in this comparison and are show in Fig. 4 as day 11. As previously mentioned, 1 day after the repeated EtOH treatment, WIN's effects on locomotor activity, nociception, Fig. 3 Effects of repeated EtOH treatments on WIN-induced effects in the mouse tetrad. Bars represent the mean (±SEM; N=11-13) value for each measure. The scales on the ordinates are expressed as number of beam breaks per session (locomotor activity), percent maximum possible effect (antinociception), change in body temperature (hypothermia), and percent immobility on the ring stand (catalepsy). Values on the abscissae represent the dose of EtOH administered for pretreatment. *p<0.05; **p<0.01; ***p<0.001, significantly different from saline control (one-way ANOVA with Bonferroni posttests) Fig. 2 Effects of WIN on the mouse tetrad in ethanol-naïve mice. Ordinates represent the mean (±SEM, N=15-24) value for each measurement and are expressed as number of beam breaks per session (locomotor activity), percent maximum possible effect (antinociception), change in body temperature (hypothermia), and percent immobility on the ring stand (catalepsy). Abscissae represent the dose (milligrams per kilogram) of WIN administered to a group of subjects. ***p<0.0001, significantly different from the vehicle control (one-way ANOVA) and body temperature were significantly blunted (Bonferroni posttests, p<0.001). There was a significant interaction of day and treatment for measurements of locomotor activity (p< 0.05) and body temperature (p<0.01). There was a significant main effect of treatment (p<0.05) but not for day for locomotor activity, and there were significant main effects of treatment (p<0.0001) and day (p<0.01) for body temperature. There was no overall interaction between day and treatment on WIN-induced antinociception (p=0.1141), but there was a significant main effect of treatment (p< 0.0001) that was probably driven by the difference in WIN sensitivity between EtOH and saline mice tested on day 11 of the study. Furthermore, like other tetrad behaviors tested on day 20 of the experiment, there was no difference between EtOH-and saline-treated mice with regard to their sensitivity to the antinociceptive effects of WIN (Bonferroni posttest, p> 0.05). These data suggest that the change in WIN sensitivity following EtOH treatment reverses within a 10-day recovery period. However, there was no overall interaction between treatment and day on WIN-induced catalepsy (p=0.0582), although EtOH-treated mice showed a trend to being more cataleptic than controls on day 20 (Bonferroni posttest, p=0.0591).
CB1 protein expression is altered in HyTh, VTA, and PAG following 10-day EtOH treatment Previous studies have reported decreases in CB1 protein (Mitrirattanakul et al. 2007 ), receptor binding (Basavarajappa et al. 1998; Vinod et al. 2006) , and G protein cycling (Basavarajappa and Hungund 1999b) in rodents chronically exposed to EtOH. Western blot analysis was used to investigate whether the 10-day EtOH treatment used in the present study also induced changes in CB1 receptor expression. Anti-CB1 antibody specificity was confirmed in western blots using crude membrane fractions from both wild-type and CB1 knockout (KO) mice. In wild-type mice, all brain regions tested showed a band that corresponded to the predicted molecular weight of full-length CB1 (≈52 kDa). This band was completely absent in samples from CB1 KO mice (Fig. 5a ) confirming antibody specificity. Experiments assessing changes to CB1 expression used tissue collected from mice after determination of BECs following repeated EtOH injections. These animals were not used for behavioral measures of the tetrad as WIN administration by itself can downregulate levels of CB1 protein (Martini et al. 2010; Martini et al. 2007; TappeTheodor et al. 2007) . As shown in the summary panels (Fig. 5b) , CB1R levels were altered in a region-dependent manner in animals treated chronically with ethanol. Ethanol decreased CB1 levels in HyTh, while it increased CB1 expression in PAG and VTA. There was a significant main effect of EtOH treatment in the VTA (two-way ANOVA, p <0.05) attributable to a significant increase in CB1 protein expression in the EtOH-treated group on day 11 (Bonferroni posttest, p< 0.05) that returned to control levels by day 20. In the HyTh, there was a Fig. 4 Effects of repeated 4.0-g/ kg EtOH treatments on WINinduced behaviors are reversible. Bars represent the mean (±SEM; N=8-13) value for each measure. The scales on the ordinates are expressed as number of beam breaks per session (locomotor activity), percent maximum possible effect (antinociception), change in body temperature (hypothermia), and percent immobility on the ring stand (catalepsy). Values on the abscissae represent the day behavioral testing was performed. ***p<0.001, significantly different from corresponding saline control (two-way ANOVA with Bonferroni posttest) significant overall interaction (two-way ANOVA, p<0.05) and main effects of EtOH treatment (p<0.01) and day (p< 0.05). This was due to a significant decrease in CB1 protein on day 11 (Bonferroni posttest, p<0.01) that returned to baseline levels on day 20. In the PAG, there was a significant main effect of EtOH treatment to increase CB1 protein expression on days 11 and 20 (two-way ANOVA, p<0.05). Finally, there was a trend for interaction between treatment and day on CB1 protein expression in the Cereb (two-way ANOVA, p=0.0522) with a reduction in CB1 protein on day 11. While EtOH treatment appeared to reduce CB1 levels in other brain regions in a time-dependent manner (frontal cortex, DStr, NAc), these changes were not statistically significant.
Discussion
The major finding of this study is that a 10-day treatment of mice with EtOH reduces the hypolocomotive, antinociceptive, and hypothermic effects of an acute dose of the cannabinoid agonist WIN. The magnitude of this response was dependent on the dose of EtOH, and importantly, was selective as no effects of EtOH were seen for WIN-induced catalepsy. In addition, the effects of EtOH treatment on WIN-induced hypolocomotion, antinociception, and hypothermia were reversible and returned to baseline levels 10 days after the last ethanol treatment. Finally, the changes in WIN-induced behaviors following the 10-day EtOH treatment protocol were 
Repeated exposures to EtOH alter the behavioral response to WIN
A behavioral interaction between EtOH and CB1 agonists has been previously reported, but these studies are limited to measures of ataxia or shock avoidance (da Silva et al. 2001; Lemos et al. 2007; Newman et al. 1974; Newman et al. 1972; Siemens and Doyle 1979; Sprague and Craigmill 1976) . In addition, considerable work has demonstrated a clear effect of alcohol on CB1 receptor expression/binding and EC signaling in both in vitro and in vivo studies (Basavarajappa et al. 1998; Basavarajappa and Hungund 1999a; Basavarajappa and Hungund 1999b; Basavarajappa et al. 2000; Basavarajappa et al. 2003; Caillé et al. 2007; Ferrer et al. 2007; Mitrirattanakul et al. 2007; Vinod et al. 2006) . These data suggest that alcohol treatment, by altering CB1 expression, should induce changes in the sensitivity of mice to other CB1-mediated behaviors. In the present study, 10 days of twice-daily EtOH injections significantly attenuated the effect of the CB1 agonist WIN on three of the four measured behaviors. To our knowledge, these data are the first to show that there is behavioral specificity with respect to the effects of chronic EtOH on cannabinoid-induced behaviors.
While WIN is a highly potent agonist at CB1 receptors, it can also activate cannabinoid type 2 (CB2) receptors, and more selective CB2 agonists are known to have analgesic properties in certain models of inflammatory and neuropathic pain (Curto-Reyes et al. 2010; Jhaveri et al. 2007; Rahn et al. 2008 ). However, the role CB2 plays in mediating the antinociceptive effects of WIN to acute pain is somewhat contentious. One study using CB1 and CB2 KO mice found the acute antinociceptive effects of WIN were due exclusively to its effects at CB2 (Ibrahim et al. 2006) . However, the doses of WIN used to test CB1 KO mice in that study were an order of magnitude lower than those used to test CB2 KOs, making it difficult to truly compare genotypic differences. In contrast, mice with a targeted deletion of CB1 in the periphery that spared central CB1 receptors demonstrated a suppression of WIN-induced antinociception at the 3.0-mg/kg dose ). These findings strongly suggest that the antinociceptive effects of WIN observed in the present work resulted from activation of the CB1 receptor.
Several observations suggest that the reduction in WIN-induced behaviors following EtOH treatment is likely to result from changes in pharmacodynamic rather than pharmacokinetic processes. If EtOH treatment enhanced metabolism of WIN, then all behaviors should be similarly affected-a finding that was not observed in the present study as measures of WIN-induced catalepsy were unaffected. In addition, the decreased responsiveness of EtOH-treated mice to WIN was dependent on the dose of EtOH administered over the 10-day treatment, but the magnitude of this effect varied between measures of locomotor activity, nociception, and body temperature. For measures of nociception, there was a significant difference in the sensitivity to WIN between all treatment groups. However, cross-tolerance to the hypolocomotive effects of WIN was only observed in mice treated with 4.0 g/kg EtOH, while the tolerance to WIN-induced hypothermia was not different between subjects given 2.0 or 4.0 g/kg EtOH. This suggests that cross-tolerance to the hypothermic effects of WIN reaches its upper threshold at lower doses of EtOH than do the other behaviors. In other words, WIN-induced hypothermia may be more sensitive to pretreatment with EtOH than other measures. These data argue that changes in CB1 receptor expression or function underlie the development of tolerance to the WIN-induced behaviors following EtOH treatment. They also suggest that that the mechanisms and brain regions underlying these changes are differentially sensitive to EtOH treatment.
The reversibility of EtOH-induced changes in WIN sensitivity
Results from previous studies indicate that changes in CB1 expression following chronic EtOH treatment are reversible. For example, CB1 protein expression in rat hippocampus is reduced after ethanol exposure, and this change recovers during withdrawal (Mitrirattanakul et al. 2007) . Similarly, ethanol-induced decreases in CB1 binding in mouse cortex, hippocampus, cerebellum, and striatum revert to control levels over a 24-h withdrawal period (Vinod et al. 2006) . In contrast, the results from the present study indicate that the effects of the CB1 agonist on tetrad behaviors remain attenuated 1 day following the last EtOH injection. This indicates that the 10-day treatment regimen produces longer lasting effects on CB1 expression than those observed after 3 days of continuous vapor inhalation (Vinod et al. 2006) . Following 10 days of recovery from the ethanol treatment, we found a significant interaction between the recovery time and treatment on WIN-induced hypolocomotion and hypothermia. Importantly, there was no interaction between these factors for WIN-induced antinociception, and the EtOH-treated mice seemed to return to baseline levels more slowly for this measure when compared to locomotor activity and body temperature. These results suggest that over the 10-day recovery period, CB1 receptor expression or function may return to control values in a region-dependent manner.
Repeated EtOH treatment alters CB1 expression in brain nuclei that underlie tetrad behaviors
In the present study, EtOH-treated mice showed alterations in CB1 receptor expression that varied across brain regions. For example, the trend for decreased CB1 expression in the cerebellum of EtOH-treated mice suggests that the crosstolerance that develops to the ataxic effects of cannabinoids following chronic ethanol exposure (da Silva et al. 2001; Lemos et al. 2007; Siemens and Doyle 1979; Sprague and Craigmill 1976) may be due to decreased expression of cerebellar CB1 receptors. Similarly, EtOH treatment decreased expression of CB1 protein in the hypothalamus and levels recovered to control values over the 10-day recovery period. These changes mirror the attenuation and recovery of WIN-induced hypothermia observed in EtOH-treated mice. As the anterior preoptic region of the hypothalamus is strongly implicated in mediating the hypothermic effects of CB1 agonists (Fitton and Pertwee 1982; Rawls et al. 2002) , these findings support the idea that the decrease in WINinduced hypothermia following EtOH treatment follows the downregulation of CB1 receptors in this area.
Cannabinoid-mediated catalepsy is thought to reflect activation of CB1 receptors in the dorsal striatum Olley 1977, 1978) , although the PAG has also been implicated (Lichtman et al. 1996) . In the present study, EtOH treatment increased CB1 protein expression in the PAG, and these mice showed a trend towards enhanced sensitivity to the cataleptic effects of WIN. Paradoxically, WIN-induced antinociception, typically thought to involve the PAG, was reduced in EtOH-treated subjects, and this effect only partially returned to baseline levels following the recovery period. Although these findings seem to be at odds, the brain nuclei associated with the antinociceptive effects of cannabinoids are numerous and widespread. In addition to the PAG (Lichtman et al. 1996; Martin et al. 1995) , the rostral ventromedial medulla (Martin et al. 1998) , amygdala, lateral posterior and submedial nuclei of the thalamus, superior colliculus, and noradrenergic A5 region are also thought to be involved in mediating the antinociceptive effects of CB1 agonists (Martin et al. 1999) . It is possible that reduced expression of CB1 receptors in one or more of these supraspinal structures, in the spinal cord itself (Lichtman and Martin 1991) , or in the periphery ) could underlie the attenuation in WIN-induced antinociception following EtOH treatment.
While cannabinoids display antinociceptive properties in and of themselves, the cannabinoid system also has substantial interactions with the opioid system. This occurs both via the formation of heterodimers between CB1 and the μ-opioid receptor (Hojo et al. 2008) as well as through downstream modulation of G αz subunits. This latter mechanism contributes to the analgesic cross-tolerance that forms between opioid and cannabinoid drugs (Garzón et al. 2009 ). In addition, cross-tolerance has been reported for the antinociceptive effects of ethanol and morphine (Malec et al. 1987 ). Although WIN is not known to directly interact with the μ-opioid receptor, it is possible that EtOH-induced alterations in μ-opioid expression or in shared signaling pathways between CB1 and the μ receptor may contribute to the cross-tolerance to WIN-induced antinociception observed in this study.
The neural substrates associated with cannabinoidinduced hypolocomotion are perhaps the least well studied of the tetrad behaviors. However, recent work indicates that cannabinoids may reduce locomotor activity via a striatal mechanism that involves A2 A receptors (Carriba et al. 2007; Lerner et al. 2010) . In the present study, there were no significant changes in CB1 expression in tissue punches containing either the DStr or NAc in ethanol-treated mice. Although these results are limited by modest anatomical resolution of the western blot studies, it is possible that decreased CB1 expression in a subpopulation of neurons (e. g., indirect pathway cells) could be masked by increased expression in another cell population.
Lastly, there was a significant increase in CB1 protein expression in the VTA 24 h following the chronic EtOH treatment, and levels returned to control values over the recovery period. The effect of chronic EtOH on VTA CB1 expression is particularly interesting given the high prevalence of co-abuse of EtOH and marijuana in humans mentioned earlier. These findings suggest that chronic ethanol exposure may enhance the rewarding properties of cannabinoids by increasing the sensitivity of VTA neurons to CB1 agonists. Conversely, cannabinoids are known to mediate certain aspects of ethanol reward and consumption. For example, CB1 antagonists including rimonabant (SR141716A) block EtOH-induced increases in the firing rate of VTA dopamine (DA) neurons (Perra et al. 2005) , and CB1 KO mice show reduced place conditioning for EtOH (Houchi et al. 2005) . CB1 KO mice also consume less alcohol in a two-bottle choice paradigm, and unlike control animals, they do not show an increased release of DA in the NAc following acute EtOH administration . Interestingly, mice that undergo repeated cycles of chronic ethanol vapor exposure and withdrawal that results in dependence show increased voluntary EtOH consumption (Becker and Lopez 2004; Griffin et al. 2009; Lopez and Becker 2005) . Combined with the data from the present study, these results suggest the possibility that increases in CB1-mediated expression and signaling in VTA neurons may underlie this change in drinking.
In conclusion, the results of this study expand upon previous work demonstrating an interaction between the ataxic effects of EtOH and cannabinoids. We demonstrate for the first time that repeated EtOH treatment results in decreased sensitivity to the hypolocomotive, antinociceptive, and hypothermic effects of the CB1 agonist WIN. Furthermore, our data indicate that these effects are accompanied by alterations in CB1 protein expression in neural substrates that are thought to underlie these behaviors. Future studies to determine the mechanism behind the observed changes in CB1 receptor expression following CET will contribute to the basic understanding of physiological processes underlying alcohol abuse and may provide insight into novel therapeutic targets.
